We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (220)12/2/2004 11:25:44 AM
From: Tadsamillionaire   of 255
Corporation (NASDAQ: ARDM) announced today that Dr. Bryan Lawlis,
President and Chief Executive Officer will present at the Robins
Small-Cap Life Sciences Investor Conference in New York on December 7,

Dr. Lawlis is scheduled to present at 1:15 p.m. EST at the Lotus
Club, located at 5 East 66th Street.

This conference presentation is being webcast and can be accessed

The Robins Small-Cap Life Sciences Conference will feature
small-cap life sciences companies expected to perform well in 2005.

Bradley Pharmaceuticals, Inc. kicks off the conference at 9:00
a.m. EST. Other presenting companies include Cardiotech International,
Inc., LifePoint, Inc., and Curon Medical, Inc..

The conference is open, free of charge, to the professional
investment community and will be moderated by Marc Robins, CFA,
founder of The Robins Group (an Institutional Broker Dealer) and
Robins Media.

About Robins Media:

Marc Robins has over 25 years of experience in the small-cap
arena, including a regularly featured column in Forbes, contributing
articles in the AAII Journal and his frequent quotes found in various
financial media. The conference is part of a series of events hosted
by Robins Media. These events showcase undervalued, under-followed
small-cap companies.

About Aradigm Corporation

Aradigm develops non-invasive delivery systems to enable patients
to comfortably self-administer biopharmaceuticals and small molecules
that would otherwise be given by injection. The company's advanced
AERx(R) pulmonary and Intraject(R) needle-free delivery technologies
offer rapid delivery solutions for liquid drug formulations. Current
development programs focus on neurological disorders, heart disease,
respiratory conditions and cancer. More information about Aradigm can
be found at
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext